VanBlargan, Laura A. http://orcid.org/0000-0002-8922-8946
Errico, John M. http://orcid.org/0000-0002-4452-8152
Halfmann, Peter J.
Zost, Seth J. http://orcid.org/0000-0001-6712-5076
Crowe, James E. Jr. http://orcid.org/0000-0002-0049-1079
Purcell, Lisa A.
Kawaoka, Yoshihiro http://orcid.org/0000-0001-5061-8296
Corti, Davide http://orcid.org/0000-0002-5797-1364
Fremont, Daved H. http://orcid.org/0000-0002-8544-2689
Diamond, Michael S. http://orcid.org/0000-0002-8791-3165
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI157155, 75N93021C00014, 75N93019C00051, R01 AI157155, 75N93019C00051, HHSN272201700060C)
Article History
Received: 15 December 2021
Accepted: 22 December 2021
First Online: 19 January 2022
Competing interests
: M.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences and Carnival Corporation and is on the Scientific Advisory Boards of Moderna and Immunome. The Diamond laboratory has received funding support in sponsored research agreements from Moderna, Vir Biotechnology and Emergent BioSolutions. J.E.C. has served as a consultant for Luna Biologics and Merck Sharp & Dohme, is on the Scientific Advisory Board of Meissa Vaccines and is the founder of IDBiologics. The Crowe laboratory has received sponsored research agreements from Takeda Vaccines, AstraZeneca and IDBiologics. Vanderbilt University has applied for patents related to two antibodies discussed in this paper. L.A.P. and D.C. are employees of Vir Biotechnology and may hold stock shares in Vir Biotechnology. L.A.P. is a former employee and shareholder in Regeneron Pharmaceuticals. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.